1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,825 | 0,925 | 28.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| JIANGSU RECBIO TECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 20.06. | RECBIO-B (02179): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 20, 2025, APPOINTMENT OF THE BOARD OBSERVER AND AMENDMENTS TO THE ARTICLES OF ... | - | HKEx | ||
| 30.05. | RECBIO-B (02179): FORM OF PROXY FOR USE AT THE 2024 ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 20, 2025 | 2 | HKEx | ||
| 30.05. | RECBIO-B (02179): NOTICE OF 2024 ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 30.05. | RECBIO-B (02179): CIRCULAR OF 2024 ANNUAL GENERAL MEETING | - | HKEx | ||
| 21.05. | RECBIO-B (02179): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 21.05. | RECBIO-B (02179): PROPOSED PARTICIPATION IN THE H SHARE FULL CIRCULATION PLAN BY THE COMPANY, PROPOSED CHANGES IN BUSINESS SCOPE, PROPOSED AMENDMENTS ... | - | HKEx | ||
| 22.04. | RECBIO-B (02179): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
| 22.04. | RECBIO-B (02179): 2024 ANNUAL REPORT | - | HKEx | ||
| 28.03. | RECBIO-B (02179): UPDATE ON THE QUALIFICATION OF THE JOINT COMPANY SECRETARY | 1 | HKEx | ||
| 28.03. | RECBIO-B (02179): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024 AND PROPOSED APPOINTMENT OF THE BOARD OBSERVER | - | HKEx | ||
| 18.03. | RECBIO-B (02179): DATE OF BOARD MEETING | - | HKEx | ||
| 27.02. | RECBIO-B (02179): ANNOUNCEMENT IN RELATION TO THE ACCEPTANCE BY THE CSRC OF THE APPLICATION MATERIALS FOR THE ISSUANCE OF DOMESTIC SHARES | 2 | HKEx | ||
| 12.02. | RECBIO-B (02179): VOLUNTARY ANNOUNCEMENT ACCEPTANCE OF THE APPLICATION FOR CLINICAL TRIAL OF THE COMPANY'S NOVEL ADJUVANTED RECOMBINANT HPV 9-VALENT ... | - | HKEx | ||
| 09.01. | RECBIO-B (02179): CORRIGENDUM OF POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON DECEMBER 24, 2024 | 3 | HKEx | ||
| 02.01. | RECBIO-B (02179): VOLUNTARY ANNOUNCEMENT COMPLETION OF ENROLLMENT OF PHASE III CLINICAL TRIAL OF THE COMPANY'S NOVEL ADJUVANTED RECOMBINANT SHINGLES ... | 1 | HKEx | ||
| 25.07.24 | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 25.07.2024 | 249 | Xetra Newsboard | The following instruments on XETRA do have their first trading 25.07.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 25.07.2024
Aktien
1 US55607P2048 Macquarie Group Ltd.... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
| HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
| CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
| QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
| SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
| KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
| CLIMB BIO | 1,180 | -5,60 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
| ALLOGENE THERAPEUTICS | 1,180 | -1,67 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
| EVOTEC | 7,138 | -0,81 % | Evotec steigt in Mega-Forschungsprojekt ein - Hoffnungsschimmer für Millionen Nierenpatienten | Evotec SE treibt seine Strategie in der personalisierten Medizin weiter voran und verkündet den Beitritt zum renommierten NURTuRE-AKI-Konsortium. Mit diesem Schritt zielt das MDAX- und TecDAX-notierte... ► Artikel lesen | |
| BIONTECH | 90,70 | -0,60 % | BioNTech schluckt CureVac! Evotec und Vidac als nächstes? Kurstreiber Übernahme und Kaufempfehlung | Steht bei Vidac Pharma eine neue Kursexplosion bevor? Im vergangenen Herbst ging es um rund 200 % nach oben. Gestern gab es eine Kaufempfehlung. Die Analysten sehen bei der Biotech-Perle Vervielfachungspotenzial.... ► Artikel lesen | |
| CARGO THERAPEUTICS | 4,190 | -0,71 % | Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 20,610 | -3,33 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target |
Das Unternehmen JIANGSU RECBIO TECHNOLOGY CO LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,005 (-0,60 %) liegt der Kurs bei 0,825 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JIANGSU RECBIO TECHNOLOGY CO LTD finden Sie auf Wallstreet Online.